Antitumor activity
PD
ADVERSE EVENTS, DISEASE
Of the 108 eligible patients who received induction chemotherapy, 101 were assessable for response to chemotherapy. Seven patients could not be assessed for response because of discontinuation during induction therapy. The reasons for discontinuation during induction therapy were: patients' refusal, four patients; adverse events, three patients; and ineligible, one patient. None of the patients showed CR, 43 (40.2%) showed PR, 48 (44.9%) showed SD, and nine (8.4%) showed PD. CR and PR were needed to confirm 4 week response duration. All patients who had experienced PR after two cycles of induction therapy maintained the response until the end of the induction therapy. Finally, the overall response rate and disease control rate to chemotherapy were 40.2% (95% confidence interval, 30.8%–50.1%) and 85.0% (95% confidence interval, 76.9%–91.2%), respectively.PFS of the two groups is shown in Figure (A) Progression‐free survival from randomization. (B) Overall survival from randomization in an intent to treat analysis. (C) Overall survival from randomization excluded for seven ALK‐positive patients.OS of the two groups is shown in Figure The OS of the two groups, except for patients who were ALK rearrangement‐positive, separated by their response to induction therapy, such as PR or SD, are shown in Figure Overall survival from randomization: response to induction chemotherapy.